Pharvaris N.V.
PHVS
Rank in Stocks
#5323
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Share Price
$34.47
Last synced: 2026-11-09
Market Cap
$2.41B
Change (1 day)
0.23%
Change (1 year)
42.91%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Pharvaris N.V. (PHVS)
Category
Healthcare
EPS for Pharvaris N.V. (PHVS)
EPS as of June 2026 TTM: $-3.01
According to Pharvaris N.V.'s latest financial reports, its current EPS (TTM) is $-3.01. At the end of 2025 the company had an EPS of $-3.48, a decrease compared to its 2024 EPS of $-2.58.
EPS history for Pharvaris N.V. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.01 | -13.48% |
| 2025 | $-3.48 | 35.03% |
| 2024 | $-2.58 | -11.24% |
| 2023 | $-2.91 | 19.40% |
| 2022 | $-2.44 | 51.86% |
| 2021 | $-1.60 | 54.89% |
| 2020 | $-1.04 | 269.06% |
| 2019 | $-0.28 | 74.33% |
| 2018 | $-0.16 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -620.11% |
US
|
|
| $-7.07 | 134.81% |
US
|
|
| $-5.29 | 75.69% |
AU
|
|
| $12.88 | -527.78% |
BE
|
|
| $21.56 | -816.06% |
NL
|
Questions about Pharvaris N.V.'s earnings per share (EPS)
What is Pharvaris N.V.'s earnings per share (EPS)?
Pharvaris N.V.'s earnings per share (EPS) over the last twelve months is $-3.01, as of Jun 2026.
What was Pharvaris N.V.'s earnings per share (EPS) in 2025?
In 2025, Pharvaris N.V.'s earnings per share (EPS) was $-3.48, compared with $-2.58 in 2024.
How has Pharvaris N.V.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Pharvaris N.V.'s earnings per share (EPS) was highest in 2020 ($-1.04) and lowest in 2025 ($-3.48).
How does Pharvaris N.V.'s earnings per share (EPS) compare with similar companies?
Pharvaris N.V.'s earnings per share (EPS) ($-3.01) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.